Statistics Bedeviled Cymbalta Fibromyalgia NDA, Derail Chronic Pain Claim
Executive Summary
The statistical dispute behind Lilly's withdrawal of its chronic pain sNDA for Cymbalta should come as no surprise to the sponsor - the issue was previewed during FDA's review of an earlier duloxetine indication, fibromyalgia